At a routine check at 18 weeks old, the baby was noted to be tachycardic with hyperdynamic pulses and a pansystolic murmur. Echocardiography which had been normal prior to commencing alpha interferon, demonstrated the presence of hypertrophic obstructive cardiomyopathy (HaCM). Treatment with propranolol and frusemide was commenced, and the prednisolone was gradually reduced. Echocardiography 3 weeks following the initial diagnosiS of HaCM showed a marked improvement, with reduction in ventricular wall thickness.
DISCUSSION
Alpha interferon was first used by White and colleagues to treat pulmonary haemangiomatosis in 1989 1 • Subsequently, there were case reports of successful use of a-interferon for cavernous haemangiomas 2 ,3. Ezekowitz et al. treated 20 infants with life-threatening haemangiomas, four of whom had Kasabach-Merritt syndrome. Eighteen of the 20 infants appeared to have a successful response to e-interferon". In one recent report-describing four infants with haemangioma who did not respond to interferon, the authors used (X-2b interferon rather than (X-2a interferon, and a three times weekly dose, rather than the daily dose used in our case and other reported cases.
Steroids have recently been implicated in the development of HaCM. Brand and colleagues reported three cases of HaCM following the use of dexamethasone for bronchopulmonary dysplasia'', In a prospective study on preterm infants treated with dexamethasone for chronic lung disease, all 11 infants in whom ventricular septal and left ventricular posterior wall thickness were measured showed some hypertrophy. In two of the 11, there was marked septal hypertrophy with left ventricular outflow tract A baby boy was delivered at 36 weeks gestation with a large facial haemangioma (Figure 1) . He had severe thrombocytopenia in the first 24 h of life (platelets 11 X 10 9/1) and he was commenced on high dose oral steroids (prednisolone 3mg/kg). The haemangioma continued to grow and the baby required frequent platelet and cryoprecipitate transfusions. Tranexamic acid was added to the treatment at 4 weeks of age with no apparent improvement.
The haemangioma increased in size rapidly and so from 6 weeks of age we started to measure the volume, initially using photographs with scaled dimensions, later using specially designed atraumatic balsa-wood callipers.
When the infant was 5 weeks old, treatment with subcutaneous alpha interferon was commenced, initially at 1 million units/rn-. This dose was increased over the following 2 weeks to 3 million units/m/. The platelet count started to rise, and the haemangioma gradually reduced in volume ( Figure 2 ). By 13 weeks of age, the volume of the haemangioma had halved and thereafter the dose of interferon was gradually reduced. Subsequent to discontinuation of the c-interferon there was only a small further reduction in the volume of the haemangioma. obstruction", All these changes were reversed when the dexamethasone was discontinued, and in the case we present, the hypertrophy reversed when the prednisolone was discontinued.
Reports of the use of steroids for cavernous haemangiomas have only shown them to be effective in about 30% of infants with giant cavernous haemangiomas''. In view of the recent successes reported in the literature, and our own successful use of c-interferon, we suggest that
